The expedition cruise ship carried passengers and crew from 23 countries, making the event an immediate multinational public‑health concern.
When the ship approached Praia, Cape Verde, several critically ill individuals required medical evacuation. At least three symptomatic patients were transferred ashore for treatment and testing.
Initial case counts were small but quickly expanded as testing and contact tracing spread across multiple countries.
No additional deaths had been reported after the initial cluster.
Samples from evacuated patients in Cape Verde were sent for laboratory analysis, including testing at the Institut Pasteur de Dakar in Senegal, where two of the three evacuated patients were confirmed to have recent infection with Andes virus, a hantavirus species.
Further international laboratory work rapidly clarified the nature of the outbreak.
Genetic sequencing of virus samples confirmed that the pathogen was Andes hantavirus (ANDV) and showed no evidence of a new mutation, helping rule out fears that a novel variant was responsible.
The investigation involved multiple reference laboratories. For example, Institut Pasteur in Paris, which hosts France’s National Reference Centre for Hantaviruses, received samples from suspected French cases linked to the voyage and supported confirmatory analysis.
This rapid sequencing effort allowed public‑health officials to quickly identify the virus and tailor containment measures.
Hantaviruses are typically transmitted from rodents to humans. The Andes virus, found mainly in parts of Argentina and Chile, is unusual among hantaviruses because limited person‑to‑person transmission has been documented in previous outbreaks.
The cruise ship’s itinerary provided a clue about the possible origin of the outbreak. The voyage had departed from Ushuaia, Argentina, a region near areas where Andes virus circulates in wildlife.
Investigators therefore considered two main possibilities:
Public reports have not identified a definitive “index case,” and the exact chain of transmission remains under investigation.
Once the cluster was identified, authorities had to track passengers and crew who had already dispersed across multiple countries.
Public‑health agencies coordinated to:
The ship itself was later docked in Rotterdam in the Netherlands, where sanitation and further investigation were carried out.
Although the cluster was relatively small, the response illustrated how modern disease surveillance works across borders.
Key features included:
Rapid international alerts. Authorities notified WHO and European surveillance networks within days of the first severe cases.
Distributed laboratory capacity. Diagnostic work involved laboratories across several regions, including testing in Senegal’s Institut Pasteur de Dakar, highlighting the growing role of African research infrastructure in outbreak response.
Fast genomic sequencing. Sequencing quickly confirmed the virus strain and ruled out a novel mutation, helping guide containment strategies.
At nearly the same time, a separate crisis was unfolding in Central Africa. In May 2026, an Ebola outbreak caused by the Bundibugyo virus was detected in the Democratic Republic of the Congo (DRC) and later in Uganda.
Laboratory analysis identifying the virus strain was performed by the Institut National de Recherche Biomédicale (INRB) in Kinshasa.
Within days:
This rapid identification and reporting demonstrated how regional laboratories are increasingly central to global surveillance rather than merely sending samples abroad for confirmation.
The MV Hondius outbreak remained limited in scale but offered a vivid example of how infectious‑disease detection works today. A rare pathogen appeared among travelers from dozens of countries, triggered medical evacuations near Cape Verde, and was genetically identified within days through coordinated international laboratory work.
With 11 cases and 3 deaths, the outbreak was serious but contained. More importantly, it showed how faster alerts, genomic sequencing, and stronger regional laboratories—particularly in Africa—are reshaping how the world detects and responds to emerging disease threats.